Targeting CPS1 in the treatment of Carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder
- PMID: 28281899
- DOI: 10.1080/14728222.2017.1294685
Targeting CPS1 in the treatment of Carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder
Abstract
Carbamoyl phosphate synthetase 1 (CPS1) deficiency (CPS1D) is a rare autosomal recessive urea cycle disorder (UCD), which can lead to life-threatening hyperammonemia. Unless promptly treated, it can result in encephalopathy, coma and death, or intellectual disability in surviving patients. Over recent decades, therapies for CPS1D have barely improved leaving the management of these patients largely unchanged. Additionally, in many cases, current management (protein-restriction and supplementation with citrulline and/or arginine and ammonia scavengers) is insufficient for achieving metabolic stability, highlighting the importance of developing alternative therapeutic approaches. Areas covered: After describing UCDs and CPS1D, we give an overview of the structure- function of CPS1. We then describe current management and potential novel treatments including N-carbamoyl-L-glutamate (NCG), pharmacological chaperones, and gene therapy to treat hyperammonemia. Expert opinion: Probably, the first novel CPS1D therapies to reach the clinics will be the already commercial substance NCG, which is the standard treatment for N-acetylglutamate synthase deficiency and has been proven to rescue specific CPS1D mutations. Pharmacological chaperones and gene therapy are under development too, but these two technologies still have key challenges to be overcome. In addition, current experimental therapies will hopefully add further treatment options.
Keywords: N-carbamoyl-L-glutamate; Urea cycle disorders; carbamoyl phosphate synthetase 1; flavonoids; gene therapy; pharmacological chaperones.
Similar articles
-
Understanding carbamoyl phosphate synthetase (CPS1) deficiency by using the recombinantly purified human enzyme: effects of CPS1 mutations that concentrate in a central domain of unknown function.Mol Genet Metab. 2014 Jun;112(2):123-32. doi: 10.1016/j.ymgme.2014.04.003. Epub 2014 Apr 18. Mol Genet Metab. 2014. PMID: 24813853
-
The Study of Carbamoyl Phosphate Synthetase 1 Deficiency Sheds Light on the Mechanism for Switching On/Off the Urea Cycle.J Genet Genomics. 2015 May 20;42(5):249-60. doi: 10.1016/j.jgg.2015.03.009. Epub 2015 Apr 1. J Genet Genomics. 2015. PMID: 26059772
-
Novel Pathogenic Variant (c.580C>T) in the CPS1 Gene in a Newborn With Carbamoyl Phosphate Synthetase 1 Deficiency Identified by Whole Exome Sequencing.Ann Lab Med. 2017 Jan;37(1):58-62. doi: 10.3343/alm.2017.37.1.58. Ann Lab Med. 2017. PMID: 27834067 Free PMC article.
-
Genetic, structural and biochemical basis of carbamoyl phosphate synthetase 1 deficiency.Mol Genet Metab. 2010 Dec;101(4):311-23. doi: 10.1016/j.ymgme.2010.08.002. Epub 2010 Aug 6. Mol Genet Metab. 2010. PMID: 20800523 Review.
-
Clinical and genetic analysis of a case of late onset carbamoyl phosphate synthase I deficiency caused by CPS1 mutation and literature review.BMC Med Genomics. 2023 Jun 26;16(1):145. doi: 10.1186/s12920-023-01569-w. BMC Med Genomics. 2023. PMID: 37365635 Free PMC article. Review.
Cited by
-
Novel pathogenic variant (c.2947C > T) of the carbamoyl phosphate synthetase 1 gene in neonatal-onset deficiency.Front Neurosci. 2022 Oct 21;16:1025572. doi: 10.3389/fnins.2022.1025572. eCollection 2022. Front Neurosci. 2022. PMID: 36340787 Free PMC article.
-
O-GlcNAcylation enhances CPS1 catalytic efficiency for ammonia and promotes ureagenesis.Nat Commun. 2022 Sep 5;13(1):5212. doi: 10.1038/s41467-022-32904-x. Nat Commun. 2022. PMID: 36064721 Free PMC article.
-
Variant in the allosteric domain of CPS1 protein associated with effectiveness of N-carbamoyl glutamate therapy in neonatal onset CPS1 deficiency.J Pediatr Endocrinol Metab. 2023 Jul 10;36(9):873-878. doi: 10.1515/jpem-2023-0210. Print 2023 Sep 26. J Pediatr Endocrinol Metab. 2023. PMID: 37427576
-
Novel Neonatal Variants of the Carbamoyl Phosphate Synthetase 1 Deficiency: Two Case Reports and Review of Literature.Front Genet. 2019 Aug 22;10:718. doi: 10.3389/fgene.2019.00718. eCollection 2019. Front Genet. 2019. PMID: 31507628 Free PMC article.
-
SWI/SNF complex subunit BAF60a represses hepatic ureagenesis through a crosstalk between YB-1 and PGC-1α.Mol Metab. 2020 Feb;32:85-96. doi: 10.1016/j.molmet.2019.12.007. Epub 2019 Dec 20. Mol Metab. 2020. PMID: 32029232 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
